Vella Bioscience Raises $7M in Seed II Funding


Vella Bioscience, Inc., a Los Angeles, CA-based femtech company, closed a $7m seed II funding round.

The round, anchored by Aaron Fleck & Associates, was raised at over $50m post-money valuation.

The company intends to use the funds to advance a product portfolio of science-driven innovations, further strengthening the promise of sexual empowerment for all women.

Led by Chief Executive Officer Nial DeMena, and Chief Operating Officer Carolyn Wheeler, Vella Bioscience provides Pleasure Serum, a clinically demonstrated pre-play topical serum that promotes increased arousal and lubrication, and intense, orgasms.

Co-founded by Dr. Harin Padma-Nathan, the lead Principal Investigator for Viagra® and Cialis®, the company’s proprietary nano-encapsulated CBD technology delivers CBD beyond the skin to relax vaginal and clitoral smooth muscle to encourage arousal and orgasm.